May 16, 2023
Via: World Pharma NewsBayer today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for its investigational drug asundexian (BAY2433334) as a potential treatment to prevent stroke and systemic embolism in people with atrial fibrillation (AF). This news […]
September 19, 2023
September 14, 2023
September 7, 2023
September 5, 2023
September 1, 2023
September 14, 2023
August 30, 2023
September 20, 2023